Compare DexCom, Inc. (DXCM) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Zoom Video Communications, Inc. — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Zoom Video Communications, Inc. trades at $97.74 (market cap $27.62B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Zoom Video Communications, Inc. for 92 Days on average.
| DXCM | ZM | |
|---|---|---|
Market Cap | $31.86B | $27.62B |
Volume | 3,607,070 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $92.34 | $111.88 |
52-Week Low | $54.84 | $72.72 |
Typical Hold Time | 62 Days | 92 Days |
Enterprise Value | $31.32B | $20.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Zoom (ZM) trades at $94.67, down 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong profitability with a net income margin of 65.19% and ROE of 32.14% for 2025. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 missed. Analyst consensus price target is $118.08, implying significant upside. News highlights include AI product launches and board appointments, supporting growth initiatives.
The outlook for ZM is positive given its robust fundamentals, earnings momentum, and Wall Street's bullish stance. Key opportunities include AI-driven revenue growth and strategic investments. Risks involve competitive pressures, execution challenges, and market volatility. The stock presents a compelling case for growth investors, though careful monitoring of quarterly performance is advised.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
